Also known as: Tissue-type plasminogen activator precursor tPA t-PA t-plasminogen activator
Alteplase is indicated for:
Population group: both men and women, only adults (18 years old or older)
Alteplase is indicated for the thrombolytic treatment in acute massive pulmonary embolism with haemodynamic instability. The diagnosis should be confirmed whenever possible by objective means such as pulmonary angiography or non-invasive procedures such as lung scanning. There is no evidence for positive effects on mortality and late morbidity related to pulmonary embolism.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: both men and women, only adults (18 years old or older)
Alteplase is indicated for thrombolytic treatment in acute myocardial infarction.
90 minutes (accelerated) dose regimen: for patients in whom treatment can be started within 6 h after symptom onset.
3 h dose regimen: for patients in whom treatment can be started between 6-12 h after symptom onset provided that the diagnosis has been clearly confirmed.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: both men and women, only adults (18 - 65 years old)
Alteplase is indicated for the fibrinolytic treatment of acute ischaemic stroke. Treatment must be started as early as possible within 4.5 hours after onset of stroke symptoms and after exclusion of intracranial haemorrhage by appropriate imaging techniques (e.g. cranial computerised tomography or other diagnostic imaging method sensitive for the presence of haemorrhage). The treatment effect is time-dependent; therefore earlier treatment increases the probability of a favourable outcome.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Alteplase is contraindicated in the following cases: